Get the Stockscreener App
4.8484
0.85%
-0.0415
After Hours:
4.85
0.0016
+0.03%
Evoke Pharma Inc stock is traded at $4.8484, with a volume of 3,805.
It is down -0.85% in the last 24 hours and up +5.40% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$4.8899
Open:
$4.6784
24h Volume:
3,805
Relative Volume:
0.10
Market Cap:
$7.20M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
-0.4396
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
+4.27%
1M Performance:
+5.40%
6M Performance:
-3.23%
1Y Performance:
-46.13%
1-Day Range:
$4.6784
$4.8792
1-Week Range:
$4.6167
$5.28
52-Week Range:
$3.54
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.8484 | 7.20M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Nantahala Capital Management, LLC Increases Stake in Evoke Pharm - GuruFocus.com
Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Nantahala Capital Management, LLC Reduces Stake in Evoke Pharma Inc - GuruFocus.com
Trane Technologies (TT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - PR Newswire
Soaring Global Digestive and Intestinal Remedies Market: Key - openPR
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Gastroparesis Pipeline Trends 2024: Clinical Trials, - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL) - Defense World
Saluda Medical secures $100m for Evoke System commercialisation - Yahoo! Voices
Gastroparesis Treatment Market Future Business Opportunities - openPR
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Here’s Why Evoke Pharma, Inc. (NASDAQ:EVOK) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Gastroparesis Treatment Market Investment Opportunities: A Guide to 2031 | Evoke Pharma, Inc., Processa - EIN News
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Head to Head Contrast: Northwest Biotherapeutics (OTCMKTS:NWBO) vs. Evoke Pharma (NASDAQ:EVOK) - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) Shares Sold by Sanctuary Advisors LLC - Defense World
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming - MSN
Financial Survey: Evoke Pharma (NASDAQ:EVOK) and Geron (NASDAQ:GERN) - Defense World
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Siga Technologies (SIGA) Stock Surges Over 5% Amid Market Activi - GuruFocus.com
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Adeia Enters into Multi-Year IP License Agreement with Canon - The Manila Times
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, - openPR
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends - GlobeNewswire
New York-Based Tech Stock Finds Massive Mid-Week Success - The Globe and Mail
Gastroparesis Treatment Market Generated Opportunities, - openPR
EVOK (Evoke Pharma) 5-Day RSI : 40.08 (As of Dec. 05, 2024) - GuruFocus.com
EVOK (Evoke Pharma) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Gray Television (GTN-N) QuotePress Release - The Globe and Mail
Mercadolibre Inc (MELI-Q) QuotePress Release - The Globe and Mail
Paramount Global Cl B (PARA-Q) QuotePress Release - The Globe and Mail
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® - GlobeNewswire
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
EVOK (Evoke Pharma) 5-Day RSI : 34.66 (As of Nov. 28, 2024) - GuruFocus.com
Dell Technologies Inc (DELL-N) QuotePress Release - The Globe and Mail
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
First Solar Inc (FSLR-Q) QuotePress Release - The Globe and Mail
Amentum Stock Is Leading the S&P 500. What We Know. - MSN
Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire
Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR
EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com
Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):